How to Navigate Synthetic Biology's Capex Intensity in a Down Market

Synthetic biology isn't cheap. As we scale our technology —and our ambitions— we need more upfront capital to build pilot facilities and fund extensive R&D. But just as synthetic biology is hitting an inflexion point, we're also subject to a down market, increased supply costs, and increased risk adversity. How can we continue to scale in less favourable economic conditions? What assurances do investors need to support far-reaching visions?